Lymphoma occurrence in patients with MPN receiving conventional therapy and/or JAK1/2 inhibitors
| . | All . | Conventionally treated . | Treated with JAK1/2 inhibitor . | Statistics . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) . | Median age . | NHL N (%) . | N (%) . | Median age . | NHL N (%) . | N (%) . | Median age . | NHL N (%) . | OR . | 95% CI . | P . | |
| MPN | 626 (100) | 71.8 | 6 (0.96) | 557 (88.98) | 72.1 | 2 (0.36) | 69 (11.2) | 70.6 | 4 (5.8) | 16 | 3-87 | .0017 |
| Female | 347 (55.43) | 71.3 | 4 (1.15) | 311 (55.83) | 72.2 | 1 (0.32) | 36 (52.17) | 67.6 | 3 (8.33) | |||
| Male | 279 (44.57) | 72.3 | 2 (0.72) | 246 (44.17) | 72 | 1 (0.41) | 33 (47.83) | 73.7 | 1 (3) | |||
| MPN (Paris) | 929 | 4 (0.43) | 872 (93.86) | 2 (0.23) | 57 (6.14) | 2 (3.51) | 15 | 2-92 | .0205 | |||
| PMF | 216 (34.5) | 70.9 | 4 (1.85) | 185 (85.65) | 70.9 | 1 (0.54) | 31 (14.35) | 70.6 | 3 (9.68) | 19 | 2-196 | .01 |
| Female | 111 (51.39) | 70.6 | 3 (2.7) | 99 (53.51) | 71.2 | 1 (1.01) | 12 (38.71) | 68.2 | 2 (16.67) | |||
| Male | 105 (48.61) | 71.3 | 1 (0.95) | 86 (46.49) | 70.9 | 0 | 19 (61.29) | 72 | 1 (5.26) | |||
| PV | 168 (26.84) | 73 | 2 (1.19) | 135 (80.36) | 74 | 1 (0.74) | 33 (19.64) | 68.3 | 1 (3.03) | |||
| Female | 82 (48.81) | 72.6 | 1 (1.22) | 61 (45.19) | 76.9 | 0 | 21 (63.64) | 64.7 | 1 (4.76) | |||
| Male | 86 (51.19) | 73.4 | 1 (1.16) | 74 (54.81) | 73.1 | 1 (1.35) | 12 (36.36) | 74.5 | 0 | |||
| ET | 232 (37.06) | 71.9 | 0 | 227 (97.85) | 72 | 0 | 5 (2.15) | 71.6 | 0 | |||
| Female | 150 (64.66) | 71.1 | 0 | 147 (64.76) | 70.9 | 0 | 3 (60) | 71.6 | 0 | |||
| Male | 82 (35.34) | 72.2 | 0 | 80 (35.24) | 72.2 | 0 | 2 (40) | 73.5 | 0 | |||
| MPNu | 10 (1.6) | 72.5 | 0 | 10 (100) | 72.5 | 0 | 0 | 0 | ||||
| Female | 4 (40) | 71.8 | 0 | 4 (40) | 71.8 | 0 | 0 | 0 | ||||
| Male | 6 (60) | 74.1 | 0 | 6 (60) | 74.1 | 0 | 0 | 0 | ||||
| . | All . | Conventionally treated . | Treated with JAK1/2 inhibitor . | Statistics . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) . | Median age . | NHL N (%) . | N (%) . | Median age . | NHL N (%) . | N (%) . | Median age . | NHL N (%) . | OR . | 95% CI . | P . | |
| MPN | 626 (100) | 71.8 | 6 (0.96) | 557 (88.98) | 72.1 | 2 (0.36) | 69 (11.2) | 70.6 | 4 (5.8) | 16 | 3-87 | .0017 |
| Female | 347 (55.43) | 71.3 | 4 (1.15) | 311 (55.83) | 72.2 | 1 (0.32) | 36 (52.17) | 67.6 | 3 (8.33) | |||
| Male | 279 (44.57) | 72.3 | 2 (0.72) | 246 (44.17) | 72 | 1 (0.41) | 33 (47.83) | 73.7 | 1 (3) | |||
| MPN (Paris) | 929 | 4 (0.43) | 872 (93.86) | 2 (0.23) | 57 (6.14) | 2 (3.51) | 15 | 2-92 | .0205 | |||
| PMF | 216 (34.5) | 70.9 | 4 (1.85) | 185 (85.65) | 70.9 | 1 (0.54) | 31 (14.35) | 70.6 | 3 (9.68) | 19 | 2-196 | .01 |
| Female | 111 (51.39) | 70.6 | 3 (2.7) | 99 (53.51) | 71.2 | 1 (1.01) | 12 (38.71) | 68.2 | 2 (16.67) | |||
| Male | 105 (48.61) | 71.3 | 1 (0.95) | 86 (46.49) | 70.9 | 0 | 19 (61.29) | 72 | 1 (5.26) | |||
| PV | 168 (26.84) | 73 | 2 (1.19) | 135 (80.36) | 74 | 1 (0.74) | 33 (19.64) | 68.3 | 1 (3.03) | |||
| Female | 82 (48.81) | 72.6 | 1 (1.22) | 61 (45.19) | 76.9 | 0 | 21 (63.64) | 64.7 | 1 (4.76) | |||
| Male | 86 (51.19) | 73.4 | 1 (1.16) | 74 (54.81) | 73.1 | 1 (1.35) | 12 (36.36) | 74.5 | 0 | |||
| ET | 232 (37.06) | 71.9 | 0 | 227 (97.85) | 72 | 0 | 5 (2.15) | 71.6 | 0 | |||
| Female | 150 (64.66) | 71.1 | 0 | 147 (64.76) | 70.9 | 0 | 3 (60) | 71.6 | 0 | |||
| Male | 82 (35.34) | 72.2 | 0 | 80 (35.24) | 72.2 | 0 | 2 (40) | 73.5 | 0 | |||
| MPNu | 10 (1.6) | 72.5 | 0 | 10 (100) | 72.5 | 0 | 0 | 0 | ||||
| Female | 4 (40) | 71.8 | 0 | 4 (40) | 71.8 | 0 | 0 | 0 | ||||
| Male | 6 (60) | 74.1 | 0 | 6 (60) | 74.1 | 0 | 0 | 0 | ||||
Bold indicates significant P values.
ET, essential thrombocythemia; MPNu, myeloproliferative neoplasm, unclassified; P, P-value, with values remaining significant (P < .05) after sex and age adjustment highlighted.